United States News Todas as matérias

Seaport Therapeutics (NASDAQ:SPTX) announced today positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial for GlyphAgo™ (SPT-320).

Aclarion (NASDAQ:ACON) announced that its Board of Directors has unanimously rejected an unsolicited, non-binding proposal from Echo Lake Capital to acquire the company at a price of $4 per share.

NextNRG (NASDAQ:NXXT) announced preliminary, unaudited financial results for May 2026, highlighting a 41% year-over-year increase in revenue to $9.3 million, compared to $6.6 million in the same month last year.

StealthGas (NASDAQ:GASS) reported a solid start to the 2026 fiscal year, with first-quarter net income reaching $15.9 million, up from $14.1 million during the same period a year earlier.

Edesa Biotech (NASDAQ:EDSA) announced favorable exploratory findings for its lead therapeutic candidate, paridiprubart, in patients suffering from acute kidney injury (AKI) and concurrent respiratory distress.

Consolidated Water (NASDAQ:CWCO), a provider of advanced water supply and treatment solutions, announced today that its board of directors has approved a quarterly cash dividend of $0.14 per share for the third quarter of 2026.

La Rosa Holdings (NASDAQ:LRHC) has released its financial results for the fiscal year ended December 31, 2025, reporting a 17% year-over-year increase in total revenue to $68.5 million.

Riyadh Air, Saudi Arabia's newest national carrier, has officially taken delivery of its first two factory-new Boeing 787-9 Dreamliners.

BioCardia (NASDAQ:BCDA) announced that minutes from a recent pre-submission (Q-Sub) meeting with the U.S. Food and Drug Administration (FDA) have provided a clearer regulatory roadmap for its CardiAMP Cell Therapy System.

Amneal Pharmaceuticals (NASDAQ:AMRX) has announced encouraging interim data from the Phase 4 ELEVATE-PD clinical trial, which evaluates the efficacy and safety of CREXONT (carbidopa and levodopa) extended-release capsules in patients living with Parkinson’s disease.

Hurco Companies (NASDAQ:HURC) announced its financial results for the second quarter of fiscal year 2026, showing significant momentum in booking activity and improved operational efficiency.

Argent Trust Company, acting as Trustee for the Sabine Royalty Trust (NYSE:SBR), has declared a cash distribution of $0.502990 per unit for June 2026.

Embraer (NYSE:EMBJ) and aircraft lessor Azorra announced an expansion of their strategic partnership on June 5, 2026, with a new firm order for 15 E195-E2 aircraft.

Seres Therapeutics (NASDAQ:MCRB) announced a series of strategic financial moves aimed at strengthening its liquidity position.

Climb Bio (NASDAQ:CLYM) announced initial Phase 1 safety and pharmacokinetic data for its lead product candidate, CLYM116, at the 2026 European Renal Association (ERA) Congress in Glasgow.

G-III Apparel Group (NASDAQ:GIII), the owner and licensee of a diverse portfolio of fashion brands, reported its financial results for the first quarter of fiscal 2027, highlighting the impact of a significant regulatory refund alongside its strategic pivot toward new brand ownership.

ABM Industries (NYSE:ABM), a prominent provider of integrated facility, engineering, and infrastructure solutions, posted record revenue for its fiscal second quarter of 2026, as the company benefited from significant expansion across its core business segments.

The Board of Directors of Trane Technologies (NYSE:TT), a global leader in climate innovation, has declared a quarterly dividend of $1.05 per ordinary share.

Gilead Sciences (NASDAQ:GILD) and Lakefront Biotherapeutics (NASDAQ:LKFT) have finalized the acquisition of Ouro Medicines, a strategic move designed to bolster their respective inflammation and immunology portfolios with next-generation T cell engager therapies.

Tuniu (NASDAQ:TOUR) today announced its unaudited financial results for the first quarter of 2026, demonstrating steady growth in its core leisure travel business.

Here Group (NASDAQ:HERE) reported unaudited financial results for the third quarter of fiscal year 2026, ending March 31, 2026, revealing a challenging period characterized by softening revenue and sustained operational losses.

Kyivstar (NASDAQ:KYIV) has announced that its subsidiary, Uklon, has signed a definitive agreement to acquire E-wings, a prominent Ukrainian operator of electric scooters and micromobility solutions.

Gilead Sciences (NASDAQ:GILD) has formally recognized the South African government’s leadership in accelerating the nationwide rollout of lenacapavir, a long-acting injectable medication designed for HIV pre-exposure prophylaxis (PrEP).

Target (NYSE:TGT) has initiated a nationwide voluntary recall of its proprietary Up & Up brand baby wipes, citing the potential for microbial contamination that poses significant health risks to consumers.